Navigation Links
Molecular Biomarkers for Cancer Detection and Management
Date:11/7/2013

London (PRWEB) November 07, 2013

New to Insight Pharma Reports is Molecular Biomarkers for Cancer Detection and Management: Technologies, Markets, and Trends. This report focuses on recent progress and new directions in this highly dynamic diagnostic field. Covering extensive background and history, commercialization, and marketing trends of cancer biomarker technologies, this report provides heavy detail of historical and evolutionary aspects of cancer biomarkers, delineating some of the difficulties researchers face in validating and commercializing their candidate assays.

Significant highlights of the report include:

•Basic research conducted in both academic and commercial settings divided into three segments: disease detection, prognosis, and companion diagnostics.
-42 detailed descriptions of copmanies (including GenomeDx Biosciences, Genomic Health, Life Technologies, Foundation Medicine, Roche Molecular Systems, and many more!).
•Commercial activity in the three foregoing sectors, and the perspective of market dynamics.
•Focuses on trends and conclusions.
•Data depicted across 15 tables and figures.

Following company descriptions and commercial applications are transcribed interviews of five individuals who are highly knowledgeable in the field, including:

•Genome Diagnostics
•Billings Clinic
•Scientia Advisors
•Cynvenio Biosystems
•Johns Hopkins University School of Medicine

Also provided in the report are survey results of 107 individuals who actively work in the cancer biomarker space. Results are depicted across 9 tables.

Table of Contents

Executive Summary
•Background and history
•Basic research
•Commercial applications
•Market dynamics
•Survey results
•Trends and conclusions

CHAPTER 1: Introduction
•Scope and contents

CHAPTER 2: Background and History
•First-generation cancer biomarkers
•Categorization of cancer biomarkers
•Disease detection biomarkers
•Prognostic biomarkers
•Companion diagnostic biomarkers
•Omic era cancer biomarkers
•Failed efforts and stumbling blocks

CHAPTER 3: Basic Research
•Screening, detection, risk, and monitoring
•Screening
•Prognosis and prediction
•Companion Diagnostics
•Metastasis
•Circulating tumor cells
•Exosomes
•MicroRNA (miRNA)

CHAPTER 4: Commercial Applications
•Screening, detection, risk assessment, and monitoring biomarkers
•Alere
•Allegro Diagnostics
•Atossa Genetics
•Biophysical Corporation
•Exact Sciences
•Exosome Diagnostics
•Matrix-Bio
•MDx Health
•Mitomics
•Myriad Genetics
•Oncimmune
•Onconome
•Predictive Biosciences
•Sphingotec
•Prognosis and prediction biomarkers
•Agendia
•Abbott Molecular
•Atossa Genetics
•Biocept
•bioTheranostics
•DiagnoCure
•GenomeDx Biosciences
•Genomic Health
•Gen-Probe
•Life Technologies
•MetaStat
•Predictive Biosciences
•Skyline Diagnostics
•Trovagene
•Veridex
•Companion diagnostic biomarkers
•20/20 GeneSystems
•Abbott Molecular
•Cynvenio
•Dako (Agilent)
•Epic Sciences
•Foundation Medicine
•Genomic Health
•Molecular Response Corp.
•Nodality
•Personal Genome Diagnostics
•Interview with founder, Luis Diaz, MD
•Qiagen
•Roche Molecular Systems

CHAPTER 5: Market Dynamics
•Competitive Environment
•Sales Estimates and Projections
•Mergers and acquisitions
•Cancer detection, risk, and prognostic assay deals
•Liquid Biopsy AB and Roche
•Oxford Gene Technology
•Abbott and Stanford University
•Ipsogen and Personal Genome Diagnostics (PDGx)
•Companion diagnostic assay deals
•Abbott and Merck
•Affymetrix and Massachusetts General Hospital (MGH)
•Agilent/Dako and Genentech
•Eli Lilly
•Foundation Medicine
•GE Healthcare and Insight Genetics
•Genomic Health and OncoMed Pharmaceuticals
•HTG Molecular Diagnostics and Merck
•Life Technologies and Others
•Qiagen and Boehringer Ingelheim
•Quintiles and Oxford Cancer Biomarkers
•Roche/Ventana and other companies
•Verastem and Labcorp
•Survey Results

CHAPTER 6: Observations and Conclusions
•Companion diagnostics
•Circulating tumor cells and nucleic acids
•EMT biomarkers
•Tumor Heterogeneity
•Costs and reimbursement

CHAPTER 7: Interview Transcripts
•Luis Diaz, MD, Associate Professor of Oncology, Johns Hopkins School of Medicine; Chief Medical Officer and Founder Personal Genome Diagnostics
•Jorge Nieva, MD, Oncologist and Hematologist,Billings Clinic,Billings Montana
•Harry Glorikian, Managing Partner and Founder, Scientia Advisors
•Paul Dempsey, Ph.D., Chief Science Officer, CynvenioBiosystems
•Scott Kern, M.D., Professor of Oncology and Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
•About Cambridge Healthtech Institute

TABLES

•Exhibit 4.1 Screening, detection, risk, and monitoring biomarkers
•Exhibit 4.2 Prognosis and prediction biomarkers
•Exhibit 4.3 Companion diagnostic biomarkers
•Exhibit 5.1 Estimated cancer biomarker manufacturer revenues (2012) and projections (2017), by segment (US$ in billions)
•Exhibit 5.2 Selected recent cancer detection, risk, and prognostic assay deals
•Exhibit 5.3 Selected recent companion diagnostic assay deals
•Exhibit 5.4 Survey: Area of respondents’ work
•Exhibit 5.5 Survey: Nature of respondents’ organization
•Exhibit 5.6 Survey: Respondents’ position within their organization
•Exhibit 5.7 Survey: Respondent’s biomarker focus (Multiple answers permitted; n=107)
•Exhibit 5.8 Survey: Respondents’ organization employs which of the following technologies for cancer biomarker detection of measurement (Multiple answers permitted; n=100)
•Exhibit 5.9 Survey: Statements regarding circulating tumor cells and nucleic acids (Multiple answers permitted; n=100)
•Exhibit 5.10 Survey: Participation in companion diagnostics (Multiple answers permitted; n=100)
•Exhibit 5.11 Survey: On a scale of 1 to 5, please rate the following entities as likely sources for new cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)
•Exhibit 5.12 Survey: On a scale of 1 to 5, please rate the following technologies as likely means for detecting or measuring cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)

FIGURES

•Figure 4.1 Cynvenio's LiquidBiopsy Platform

Read the full report:

Molecular Biomarkers for Cancer Detection and Management

http://www.reportbuyer.com/countries/north_america/usa/molecular_biomarkers_cancer_detection_management.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11313928.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
2. Molecular probes identify changes in fibronectin that may lead to disease
3. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
4. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
5. Scientists discover distinct molecular subtype of prostate cancer
6. New molecular structure offers first picture of a protein family vital to human health
7. Grb2 holds powerful molecular signaling pathway in check
8. Better treatment for brain cancer revealed by new molecular insights
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
11. Molecular switch identified that controls key cellular process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... When an Au Pair comes all the way ... they are in for and they are often worried things won’t go well. More often ... for. This year’s Au Pair of the Year winner’s all commented how their Au Pairs ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination ... 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination ... garnering increased attention from all stakeholders in the development of new chemical entities. ...
(Date:2/12/2016)... CULVER CITY, California (PRWEB) , ... February 12, 2016 , ... ... to announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco ... and healthy way to stay hydrated before the big event. The invitation-only gifting suite, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology: